Disturbed sleep is a prominent feature of fibromyalgia symptomatology and has been proposed as one of the core symptoms that should be systematically assessed in clinical trials for the treatment ...

Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med. 11 , 180–194 (2010).

Recognizing these underlying principles is essential in devising holistic treatment approaches that address the multifaceted nature of fibromyalgia and empower individuals to regain control over ...

Coping with fibromyalgia as a parent can feel overwhelming, but avoiding common pitfalls makes a big difference. In this ...

More than 93% of our patients report improvements in their symptoms, with many able to reduce or stop medications that cause adverse side effects. An impressive 45% of fibromyalgia patients have ...

Fibromyalgia sufferers around the world are in need of relief. Tonix is hoping that a new treatment option may soon be available. Tonix Pharmaceuticals awaits the FDA decision on NDA acceptance ...

TNX-102 SL was granted Fast Track designation for fibromyalgia by the FDA in July of 2024. Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill ...

Fibromyalgia affects more than 10 million adults in the U.S. who are mostly women TNX-102 SL has the potential to be the first member of a new class of analgesic drugs for fibromyalgia and the first ...